Definitive Contract 75A50121C00044
Award Date
4/26/21
Potential Completion Date
11/30/22
Potential Value
$749K
Awardee
Enalare Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Princeton, NJ, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
999
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $55,766,220 federal contract was awarded by the Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Enalare Therapeutics Inc., a for-profit pharmaceutical company. The contract aims to advance Enalare's "agnostic respiratory stimulant" as a medical countermeasure to treat respiratory depression. This contract is part of a larger Broad Agency Announcement (BAA) from ASPR's Biomedical Advanced Research and...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Esperovax Inc. a $484,643 firm fixed price definitive contract to develop host-directed therapeutic candidates for mitigating long-term effects of respiratory distress. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought proposals for candidates aiding long-term outcomes from lung injury through Area of...
The U.S. Defense Health Agency awarded a $2,234,650 fixed-price level of effort contract to Inhalon Biopharma, Inc., a biopharmaceutical company focused on developing inhaled monoclonal antibody therapies for respiratory infections. The contract (ID HT942524C0076) is for developing IN-007, an inhaled treatment that utilizes human ACE2 to target and neutralize various pathogens. The work, which will be performed at Inhalon's facilities in Morrisville, North Carolina, involves activities such as...
The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $70,000 firm fixed-price contract to Oncotelic Inc. to develop TGF-β therapeutics against the long-term effects of respiratory distress post COVID-19. The contract, which does not have a set-aside designation, has a period of performance ending on June 30, 2023. This contract supports the agency's efforts to address the medical challenges posed by the COVID-19 pandemic.
Xequel Bio, Inc., doing business as FSR, was awarded a $749,999 firm fixed price definitive contract from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support research under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002. Special Instructions 019 seeks host-directed therapeutic candidates to aid long-term outcomes from lung injury. Under the contract, FSR will pursue safety review of such...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $575,000 firm fixed price definitive contract to Current Health LIMITED of Great Britain, United Kingdom. The contract supports development of real-time digital biomarker algorithms to enable early detection and improved management of SARS-CoV-2/COVID-19 infection, as requested in Special Instructions 019 under the agency's Easy Broad Agency Announcement BAA-20-100-SOL-0002....
Arete Biosciences, LLC was awarded a $745,000 firm fixed price definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop an ultra-sensitive and cost-effective home-based disposable molecular platform for SARS-CoV-2 testing. The contract is being performed in Chicago, Illinois over a period of one year from June 2022 through August 2023. The award is responsive to Special Instructions 019 under the HHS ASPR Easy...
Bioaegis Therapeutics Inc. was awarded a $749,000 firm fixed price definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to develop a safe and effective therapeutic to mitigate severe outcomes including mortality in patients with severe infection or sepsis of any etiology. This award was made under Special Instructions 019 to the department's Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought host-directed...
This is a $749,999.00 Firm Fixed Price contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Isola Therapeutics Inc. for research and development of endobronchial lavage (EBL) to prevent and treat lung damage from pulmonary chemical agents. The contract is part of the agency's "Redirect" program, which focuses on repurposing drugs in response to chemical threats. The contract does not have a set-aside designation and is scheduled...